Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Scientists who reprogrammed skin cells into brain cells say their research could lay the groundwork for new ways to treat Alzheimer's and other brain diseases.
A team of scientists has discovered what could be a novel source for researching and potentially treating Alzheimer's disease and other conditions involving the destruction of brain cells.
Gladstone Cardiovascular Disease Research Director Dr. Deepak Srivastava is quoted in this report of a breakthrough finding from UC Berkeley.
When San Francisco-based Salesforce said in 2010 it was moving into Mission Bay, many in the life sciences community were disappointed that the medical and biotech enclave would be filled by high tech workers.
Bruce Spaulding, one of the architects of San Francisco’s Mission Bay biotech enclave, is retiring for health reasons from the foundation supporting the Gladstone Institutes.
Deepak Srivastava, a cardiovascular researcher at the Gladstone Institute in San Francisco, was awarded a $6.3 million grant from the agency today, one of about twenty investigators to receive funds for translational programs.
A study led by a Johns Hopkins neuroscientist and published in the May 10 issue of the journal Neuronsuggests a potential new therapeutic approach for improving memory and interrupting disease progression in patients with a form of cognitive impairment that often leads to full-blown Alzheimer’s disease.
Rare is the soiree that makes science sizzle. But that was the fact last week during the Gladstone Institutes Gala at the Four Seasons Hotel, where 450 guests were greeted by lab-coat-wearing waiters bearing test tubes filled with cocktails.
Gladstone Institutes' Senior Investigator Dr. Shinya Yamanaka is profiled for his pioneering work in stem cell technology.
SILVER SPRING, Md. — A drug already used to treat H.I.V.infection should also be approved to prevent it, an advisory panel to the Food and Drug Administration said on Thursday. The recommendation is the first time that government advisers have advocated giving antiviral medicine to healthy people who might be exposed through sexual activity to the virus that causes AIDS.